Comparative Pharmacology
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus MICONAZOLE 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAD SHOULDERS CONDITIONER versus MICONAZOLE 3.
HEAD & SHOULDERS CONDITIONER vs MICONAZOLE 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable; this is a cosmetic conditioner. No pharmacological mechanism.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability, leakage of cellular contents, and fungal cell death.
Not applicable. Head & Shoulders Conditioner is a cosmetic product for external use on hair and scalp; no systemic dosing.
For vaginal candidiasis: 200 mg (one suppository) intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
Not applicable for systemic elimination; local retention on hair/scalp lasts until next wash (typically 24-48 hours).
Terminal half-life is approximately 24 hours (range 20-30 hours) following topical vaginal application; prolonged in hepatic impairment.
Renal (urine): <1% unchanged; biliary/fecal: <1% as parent compound; majority remains on hair/scalp and is removed via washing and shedding. Systemic absorption negligible.
Primarily hepatic metabolism; <1% excreted unchanged in urine; fecal elimination accounts for ~50% of metabolites.
Category C
Category A/B
Antifungal/Antidandruff
Antifungal